Table 1.
Patient disposition.
| Patient disposition, n (%) | Placebo + vemurafenib | Cobimetinib + vemurafenib |
|---|---|---|
| Study disposition | n = 248 | n = 247 |
| Discontinued from studya | 248 (100) | 247 (100) |
| Death | 167 (67) | 157 (64) |
| Lost to follow-up | 8 (3) | 4 (2) |
| Withdrawal by patient | 20 (8) | 21 (9) |
| Physician decision | 1 (<1) | 4 (2) |
| Other | 4 (2) | 2 (1) |
| Treatment disposition | n = 245 | n = 248 |
| Discontinued study treatment | 245 (100) | 248 (100) |
| Progressive disease | 185 (76) | 145 (58) |
| Adverse event | 21 (9) | 43 (17) |
| Death | 3 (1) | 4 (2) |
| Other | 19 (8) | 56 (23) |
aForty-eight patients in the placebo + vemurafenib arm and 59 patients in the cobimetinib + vemurafenib arm remained on study at the time of study termination.